These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19009183

  • 1. [Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].
    Santos AM, Noronha EF, Ferreira LA, Carranza-Tamayo CO, Cupolillo E, Romero GA.
    Rev Soc Bras Med Trop; 2008; 41(5):444-8. PubMed ID: 19009183
    [Abstract] [Full Text] [Related]

  • 2. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G, Tavakoli-kia R.
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
    Iraji F, Sadeghinia A.
    Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
    [Abstract] [Full Text] [Related]

  • 10. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL, Ribeiro CS, França-Costa J, Dourado MEF, Trinconi CT, Yokoyama-Yasunaka JKU, Malta-Santos H, Borges VM, Carvalho EM, Uliana SRB.
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [Abstract] [Full Text] [Related]

  • 11. Topical paromomycin for New World cutaneous leishmaniasis.
    Sosa N, Pascale JM, Jiménez AI, Norwood JA, Kreishman-Detrick M, Weina PJ, Lawrence K, McCarthy WF, Adams RC, Scott C, Ransom J, Tang D, Grogl M.
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
    [Abstract] [Full Text] [Related]

  • 12. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB, Hamida MB, Hammami H, Jannet SB, Badri T, Fenniche S, Mokhtar I.
    Dermatol Ther; 2012 May; 25(6):615-8. PubMed ID: 23210761
    [Abstract] [Full Text] [Related]

  • 13. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU, Lemke KR.
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [Abstract] [Full Text] [Related]

  • 14. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G, Kroeger A.
    Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF, Vasconcellos ÉCFE, Ribeiro CO, Lyra MR, Saheki MN, Salgueiro MM, Antonio LF, Schubach AO.
    Rev Soc Bras Med Trop; 2017 Aug; 50(2):269-272. PubMed ID: 28562769
    [Abstract] [Full Text] [Related]

  • 17. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
    Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H.
    Clin Infect Dis; 2007 Jun 15; 44(12):1549-54. PubMed ID: 17516397
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC, Rabello A, Cota GF.
    PLoS One; 2017 Jun 15; 12(9):e0184777. PubMed ID: 28926630
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.